Atopic dermatitis: An overview

American Family Physician

Volumn 86, Issue 1, 2012, Pages 35-42

  Berke, Rebecca ^a   Singh, Arshdeep ^a   Guralnick, Mark ^a,b  

^a KAISER PERMANENTE   (United States)

^b Southern California Permanente Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CERAVE; CETAPHIL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; EMOLLIENT AGENT; FILAGGRIN; GAMMA1B INTERFERON; LANOLIN ALCOHOL; PETROLATUM; PIMECROLIMUS; PSEUDOMONIC ACID; RESTORADERM; TACROLIMUS; UNCLASSIFIED DRUG; XIPAMIDE;

ACNE; ACUTE DISEASE; ADRENAL SUPPRESSION; AGE; APPLICATION SITE BURNING; ARTICLE; ATOPIC DERMATITIS; ATROPHY; BACTERIAL INFECTION; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; GROWTH RETARDATION; HERBAL MEDICINE; HOMEOPATHY; HUMAN; LYMPHOMA; PHOTOTHERAPY; PRESCRIPTION DRUG; SCRATCHING; SIDE EFFECT; SKIN CANCER; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS; STRIA; TELANGIECTASIA; ULTRAVIOLET RADIATION; VIRUS INFECTION; XEROSIS;

EID: 84863894329     PISSN: 0002838X     EISSN: 15320650     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010;30(3):269-280.
2. Wolff KL, Johnson RI. Atopic dermatitis. In: Wolff K, Johnson RA, Fitz-patrick TB. Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology. 6th ed. New York, NY: McGraw-Hill Medical; 2009:34-36.
3. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73.
4. Hanifn JM, Reed ML; Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18(2):82-91.
5. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984-992.
6. Maintz L, Novak N. Getting more and more complex: the pathophysiol-ogy of atopic eczema. Eur J Dermatol. 2007;17(4):267-283.
7. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361(9352):151-160.
8. Brenninkmeijer EE, Schram ME, Leefang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754-765.
9. Gu H, Chen XS, Chen K, et al. Evaluation of diagnostic criteria for atopic dermatitis: validity of the criteria of Williams et al. in a hospital-based setting. Br J Dermatol. 2001;145(3):428-433.
10. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406-416.
11. National Collaborating Centre for Women's and Children's Health. Atopic eczema in children: management of atopic eczema in children from birth up to the age of 12 years. London, United Kingdom: RCOG Press; 2007. http://www.nice.org.uk/nicemedia/live/11901/38559/38559.pdf. Accessed January 30, 2012.
12. Hanifn JM, Cooper KD, Ho VC, et al. Guidelines of care of atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines" [published correction appears in J Am Acad Dermatol. 2005; 52(1):156]. J Am Acad Dermatol. 2004;50(3):391-404.
13. Ellis C, Luger T, Abeck D, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol. 2003;148(suppl 63):3-10.
14. Green C, Colquitt JL, Kirby J, Davidson P. Topical corticosteroids for atopic eczema: clinical and cost effectiveness of once-daily vs. more frequent use. Br J Dermatol. 2005;152 (1):130-141.
15. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force [published correction appears in J Am Acad Dermatol. 2006;55(2):271]. J Am Acad Dermatol. 2006;54(5):818-823.
16. Ashcroft DM, Chen LC, Garside R, Stein K, Williams HC. Topical pimecro-limus for eczema. Cochrane Database Syst Rev. 2007;(4):CD005500.
17. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tol-erability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005; 330(7490):516-525.
18. Reitamo S, Wollenberg A, Schöpf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000; 136(8):999-1006.
19. Reitamo S, Ortonne JP, Sand C, et al.; European Tacrolimus Ointment Study Group. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152 (6): 1282-1289.
20. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4): 808-816.
21. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology. 2007;214(4):289-295.
22. Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006; 117 (1): e118-e128.
23. Pariser D. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther. 2009;16(3):264-273.
24. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163(1):12-26.
25. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1-191.
26. Krakowski AC, Eichenfeld LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4):812-824.
27. Grimalt R, Mengeaud V, Cambazard F; Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007; 214 (1): 61-67.
28. Habif T P. Topical therapy and topical steroids. In: Clinical Dermatology: A Color Guide To Diagnosis and Therapy. 4th ed. Mosby: New York, NY; 2004:27.
29. Berth-Jones J, Damstra RJ, Golsch S, et al.; Multinational Study Group. Twice weekly futicasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ. 2003;326(7403):1367.
30. Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje A P. Efficacy and safety of futicasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol. 2009;20(1):59-66.
31. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insuffciency: clinical implications. Am J Clin Dermatol. 2002;3(3): 141-147.
32. Ellison JA, Patel L, Ray DW, David TJ, Clayton PE. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Pediatrics. 2000;105(4 pt 1):794-799.
33. Werfel T. Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. J Dtsch Dermatol Ges. 2009;7(9):739-742.
34. Paller AS, Lebwohl M, Fleischer AB Jr, et al.; US/Canada Tacrolimus Ointment Study Group. Tacrolimus ointment is more effective than pimecro-limus cream with a similar safety profle in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol. 2005;52(5):810-822.
35. Suh L, Coffn S, Leckerman KH, Gelfand JM, Honig PJ, Yan AC. Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol. 2008;25(5):528-534.
36. Abeck D, Mempel M. Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol. 1998;139(suppl 53):13-16.
37. Klein PA, Clark RA. An evidence-based review of the effcacy of anti-histamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999;135 (12):1522-1525.
38. Zhang W, Leonard T, Bath-Hextall F, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2005;(2):CD002291.
39. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008;(4): CD006135.